ALNYLAM PHARMACEUTICALS INC (ALNY) 233.37 +3.62 (+1.58%)
233.37 +3.62 (+1.58%)
US02043Q1076 - Common Stock - After market: 238.07 +4.7 (+2.01%)
Fundamental Rating
Overall ALNY gets a fundamental rating of 3 out of 10. We evaluated ALNY against 641 industry peers in the Biotechnology industry. The financial health of ALNY is medium. Also its profitability is quite bad. ALNY shows excellent growth, but is valued quite expensive already.
Note: ALNY has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
Profitability
Profitability Rating
ALNY has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for ALNY.
VS Industry
Valuation
Valuation Rating
The Price/Earnings Ratio is negative for ALNY. In the last year negative earnings were reported.
Also next year ALNY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry
Growth
Growth Rating
ALNY is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 27.20% yearly.
The Revenue has grown by 28.23% in the past year. This is a very strong growth!
The Revenue has been growing by 78.04% on average over the past 5 years. This is a very strong growth!
Based on estimates for the next 5 years, ALNY will show a very strong growth in Revenue. The Revenue will grow by 35.97% on average per year.
The earnings per share for ALNY have decreased strongly by -29.65% in the last year.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -29.65% | -35.43% | 9.26% | 21.57% | 27.2% |
| Revenue | 78.04% | 124.22% | 28.23% | 23.25% | 34.71% | 38.96% | 35.97% |
Health
Health Rating
ALNY has a Current Ratio of 3.48. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
ALNY has a Quick Ratio of 3.33. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
The Altman-Z score of ALNY is much better than the industry average of -0.10.
ALNY has an Altman-Z score of 2.45. This is not the best score and indicates that ALNY is in the grey zone with still only limited risk for bankruptcy at the moment.
When comparing the Current Ratio of ALNY to the average industry Current Ratio of 6.18, ALNY is less able to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.05, ALNY is worse placed to pay its short term obligations than its industry peers.
ALNY has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for ALNY.
VS Industry
Quick Ratio (3.33) VS Industry: 28% outperformed.
0.04
84.53
Current Ratio (3.48) VS Industry: 29% outperformed.
0.08
85.09
Altman-Z (2.45) VS Industry: 66% outperformed.
-2,801.75
658.20
Dividend
Dividend Rating
No dividends for ALNY!.
ALNYLAM PHARMACEUTICALS INC233.37
NASDAQ:ALNY (2/3/2023, 7:24:31 PM)+3.62 (+1.58%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 10-27 2022-10-27/bmo | Earnings (Next) | 02-08 2023-02-08/amc |
| Inst Owners | 103.41% | Inst Owner Change | -1.46% |
| Ins Owners | 0.06% | Ins Owner Change | 9.75% |
| Market Cap | 28.71B | Analysts | 79.38 |
| Price Target | 247.91 (6.23%) | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Dividend Growth(5Y) | N/A | DP | N/A |
| Div Incr Years | N/A | Div Non Decr Years | N/A |
| Ex-Date | N/A | ||
| EPS beat(2) | N/A | Avg EPS beat(2) | -43.38% |
| Min EPS beat(2) | -49.37% | Max EPS beat(2) | -37.39% |
| EPS beat(4) | N/A | Avg EPS beat(4) | -32.7% |
| Min EPS beat(4) | -49.37% | Max EPS beat(4) | -6.57% |
| Revenue beat(2) | N/A | Avg Revenue beat(2) | -12.52% |
| Min Revenue beat(2) | -13.86% | Max Revenue beat(2) | -11.18% |
| Revenue beat(4) | 1 | Avg Revenue beat(4) | -7.66% |
| Min Revenue beat(4) | -14.09% | Max Revenue beat(4) | 8.49% |
| PT rev (1m) | 0.45% | PT rev (3m) | 2.12% |
| EPS NQ rev (1m) | -7.11% | EPS NQ rev (3m) | -10.2% |
| EPS NY rev (1m) | 0% | EPS NY rev (3m) | -26.48% |
| Revenue NQ rev (1m) | 0.25% | Revenue NQ rev (3m) | -0.7% |
| Revenue NY rev (1m) | 0% | Revenue NY rev (3m) | -1.41% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 29.88 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
| EPS(TTM) | -9.14 | EY | N/A |
| EPS(NY) | -5.74 | Fwd EY | N/A |
| FCF(TTM) | -5.13 | FCFY | N/A |
| OCF(TTM) | -4.55 | OCFY | N/A |
| SpS | 7.81 | BVpS | -0.55 |
| TBVpS | -0.55 | PEG (NY) | N/A |
| PEG (5Y) | N/A | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | 83.85% |
| ROICexgc(3y) | N/A | ROICexcg growth 3Y | N/A |
| ROICexcg growth 5Y | N/A | ROICexc(3y) | N/A |
| ROICexc growth 3Y | N/A | ROICexc growth 5Y | N/A |
| OM growth 3Y | N/A | OM growth 5Y | N/A |
| PM growth 3Y | N/A | PM growth 5Y | N/A |
| GM growth 3Y | -5.1% | GM growth 5Y | N/A |
| F-Score | 2 | Asset Turnover | 0.27 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 174.11% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.33 | ||
| Altman-Z | 2.45 |
| F-Score | 2 | WACC | 8.98% |
| ROIC/WACC | N/A | Cap/Depr(3y) | 392.66% |
| Cap/Depr(5y) | 787.68% | Profit Quality(3y) | N/A |
| Profit Quality(5y) | N/A | ||
| EPS 1Y | -29.65% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | -64.02% |
| EPS Next Y | -35.43% | EPS Next 2Y | 9.26% |
| EPS Next 3Y | 21.57% | EPS Next 5Y | 27.2% |
| Revenue growth 1Y | 28.23% | Revenue growth 3Y | 124.22% |
| Revenue growth 5Y | 78.04% | Revenue growth Q2Q | 40.86% |
| Revenue Next Year | 23.25% | Revenue Next 2Y | 34.71% |
| Revenue Next 3Y | 38.96% | Revenue Next 5Y | 35.97% |
| EBIT growth 1Y | -11.67% | EBIT growth 3Y | N/A |
| EBIT growth 5Y | N/A | EBIT Next Year | -6.19% |
| EBIT Next 3Y | 30.89% | EBIT Next 5Y | 34.68% |
| FCF growth 1Y | 18.52% | FCF growth 3Y | N/A |
| FCF growth 5Y | N/A | OCF growth 1Y | 18.66% |
| OCF growth 3Y | N/A | OCF growth 5Y | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA